Related Experiment Video

Updated: Jun 24, 2026

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology
06:24

Generic Protocol for Optimization of Heterologous Protein Production Using Automated Microbioreactor Technology

Published on: December 15, 2017

Microbial factories for recombinant pharmaceuticals

Neus Ferrer-Miralles1, Joan Domingo-Espín, José Luis Corchero

  • 1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain. antoni.villaverde@uab.cat.

Microbial Cell Factories
|March 26, 2009
PubMed

Insights

Microbial systems like bacteria and yeast are robust hosts for producing approved recombinant protein drugs, despite challenges in mammalian protein production. Their continued use highlights their effectiveness in biopharmaceutical manufacturing.

Area of Science:

  • Biotechnology and Biopharmaceutical Manufacturing
  • Recombinant Protein Production
  • Microbial Host Systems

Background:

  • 151 recombinant pharmaceuticals approved by FDA/EMEA primarily use microbial hosts (bacteria, yeast).
  • Microbial systems present challenges: unconventional post-translational modifications, proteolytic instability, poor solubility, and cell stress responses.
  • Despite challenges, microbial systems remain powerful tools for recombinant protein production.

Purpose of the Study:

  • To summarize the nature, properties, and applications of approved recombinant pharmaceuticals.
  • To comparatively analyze features of current and potential microbial host systems for protein drug production.

Main Methods:

  • Review and comparative analysis of existing literature on recombinant pharmaceuticals.
  • Evaluation of microbial production systems (Escherichia coli, Saccharomyces cerevisiae) and their performance.
  • Assessment of challenges and advantages associated with microbial protein production.

Main Results:

  • Microbial systems, particularly E. coli and S. cerevisiae, are extensively used and proven robust for producing approved recombinant drugs.
  • The market entry of protein drugs from non-microbial systems has not diminished the development of microbially produced biologics.
  • Despite inherent production bottlenecks, microbial systems offer a reliable platform for biopharmaceutical development.

Conclusions:

  • Microbial cellular systems are indispensable and robust platforms for the production of a significant number of biopharmaceuticals.
  • Continued innovation in microbial strain development and process optimization is crucial for future recombinant protein drug manufacturing.
  • Comparative analysis of host systems underscores the enduring value and potential of microbial production platforms.

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells08:15

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

Related Concept Videos

Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Scale-Up Processes01:14

Scale-Up Processes

The scale-up of microbial fermentation processes is essential in industrial biotechnology, allowing the transition from laboratory-scale experiments to commercial-scale production while aiming to maintain product yield and quality. This process requires meticulous adjustment of equipment design, process parameters, and contamination control strategies to accommodate increasing culture volumes.At the laboratory scale, cultures are typically maintained in 1 to 10-liter glass or autoclavable...
Bioreactor Controls-III01:22

Bioreactor Controls-III

Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...